The Role Of Condition-Specific Preference-Based Measures In Health Technology Assessment by Rowen, D.L. et al.
This is a repository copy of The Role Of Condition-Specific Preference-Based Measures In
Health Technology Assessment.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/118044/
Version: Accepted Version
Article:
Rowen, D.L. orcid.org/0000-0003-3018-5109, Brazier, J., Ara, R. et al. (1 more author) 
(2017) The Role Of Condition-Specific Preference-Based Measures In Health Technology 
Assessment. PharmacoEconomics, 35 (Suppl 1). pp. 33-41. ISSN 1170-7690 
https://doi.org/10.1007/s40273-017-0546-9
The final publication is available at Springer via 
http://dx.doi.org/10.1007/s40273-017-0546-9
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1 
 
The Role Of Condition-Specific Preference-Based Measures In Health Technology Assessment 
Running title: Condition-specific preference-based measures in HTA 
 
Authors: Donna Rowen
1
, PhD; John Brazier
1
, PhD; Roberta Ara
1
, MSc; Ismail Azzabi Zouraq, MSc
2
  
 
1 
School of Health and Related Research (ScHARR), University of Sheffield 
2
Takeda Pharmaceuticals International AG 
 
 
Corresponding Author:  
Donna Rowen 
School of Health and Related Research (ScHARR) 
University of Sheffield 
Regent Court, 30 Regent Street 
Sheffield, S1 4DA, UK 
Tel: +44 (0) 114 222 0728 
Email: d.rowen@sheffield.ac.uk 
 
 
  
2 
 
ABSTRACT 
A condition-specific preference-based measure (CSPBM) is a measure of health related quality of life 
(HRQoL) that is specific to a certain condition or disease and that can be used to obtain the quality 
adjustment weight of the quality adjusted life year (QALY) for use in economic models. This article 
provides an overview of the role of CSPBMs, the development of CSPBMs, and presents a description 
of existing CSPBMs in the literature. The article also provides an overview of the psychometric 
properties of CSPBMs in comparison to generic preference-based measures (generic PBMs), and 
considers the advantages and disadvantages of CSPBMs in comparison to generic PBMs. 
CSPBMs typically include dimensions that are important for that condition but may not be important 
across all patient groups.  There are a large number of CSPBMs across a wide range of conditions, 
and these vary from covering a wide range of dimensions to more symptomatic or uni-dimensional 
measures. Psychometric evidence is limited but suggests that CSPBMs offer an advantage in more 
accurate measurement of milder health states.  The mean change and standard deviation can differ 
for CSPBMs and generic PBMs, and this may impact on incremental cost-effectiveness ratios.  
CSPBMs have a useful role in HTA where a generic PBM is not appropriate, sensitive or responsive.  
However due to issues of comparability across different patient groups and interventions, their 
usage in health technology assessment is often limited to conditions where it is inappropriate to use 
a generic PBM or sensitivity analyses. 
 
KEY POINTS FOR DECISION MAKERS  
x A condition-specific preference-based measure (CSPBM) is a measure of HRQoL that is 
specific to a condition or disease that also has a set of preference weights that enable a 
health state utility value to be generated each time the measure is completed. 
x CSPBMs have a useful role in Health Technology Assessment (HTA) where a generic 
preference-based measure (generic PBM) is not appropriate, sensitive or responsive as they 
can provide appropriate health state utility values that capture change in that condition. 
x Due to issues of comparability across different patient groups and interventions, the usage 
of CSPBMs in HTA is generally limited to interventions where it is inappropriate to use a 
generic PBM. 
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1 What is a condition-specific preference based measure of health? 
This paper provides a definition of a condition-specific preference-based measure (CSPBM) of health 
or health-related quality of life and critically examines its role in HTA and beyond. The paper 
provides an overview and summary of all existing CSPBMs, thus providing a resource of references 
for all CSPBMs across all conditions that have been derived in the literature. The paper also 
summarises available psychometric evidence on the performance of CSPBMs, and provides guidance 
on the advantages and disadvantages of using CSPBMs for HTA in comparison to generic preference-
based measures such as the EQ-5D. 
A condition-specific preference-based measure (CSPBM) is a measure of health-related quality of life 
that is specific to a certain condition or disease and that also has a set of preference weights that 
enables a utility value to be generated from responses to the measure. Analogously to generic 
measures, a CSPBM consists of 1) items or questions that are typically completed by the patient to 
report their own health, 2) a classification system which is used to classify the self-reported health of 
the patient into a health state, and 3) a value set that enables a utility value to be produced for 
every health state described by the classification system. CSPBMs typically include dimensions that 
are important for that condition but generally not important across all patient groups. Each CSPBM 
is unique and their content varies substantially. Some CSPBMs include a range of dimensions 
covering both generic and condition-specific aspects (for example a cancer-specific measure with 
dimensions of physical functioning, role functioning, pain, emotional functioning, social functioning, 
fatigue and sleep disturbance, nausea, and constipation and diarrhoea [2]), whereas others are 
focussed upon symptoms (for example a measure for flushing (a side-effect of niacin medications) 
with dimensions of redness of skin, warmth of skin, tingling of skin, itching of skin, and difficulty 
sleeping [3]). Some CSPBMs are uni-dimensional and have several items relating to the same 
dimension (for example the measure for flushing [3]), whereas others are multi-dimensional (for 
example the measure for cancer [2]). CSPBMƐĐĂŶďĞĚĞǀĞůŽƉĞĚĨƌŽŵŶĞǁ ? ?ĚĞŶŽǀŽ ? ?ŽƌĐĂŶďĞ
derived from an existing condition-specific measure.  
 
 
2 What is the role of condition-specific preference-based measures? 
CSPBMs have a role in HTA where a generic PBM is not appropriate, or has poor psychometric 
performance in a condition or patient group, as they provide appropriate utility values under these 
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circumstances. Where a generic PBM has been shown to perform poorly in terms of sensitivity or 
responsiveness (for example, vision and hearing, severe and complex mental health problems, and 
dementia, as discussed in section 2) it is not expected that it will accurately capture the impact of an 
intervention on the HRQoL of the patient. For example, if a generic PBM has been shown to suffer 
from ceiling effects for a condition then an improvement in HRQoL following an intervention cannot 
be captured. In addition a generic PBM may fail to capture all aspects of HRQoL that are important 
for that patient group. In contrast, CSPBMs are designed to capture the aspects of HRQoL that are 
important for that condition, and unlike a generic PBM this is likely to include symptoms, sometimes 
alongside more generic dimensions of HRQoL ((for example a cancer-specific measure with 
dimensions of physical functioning, role functioning, pain, emotional functioning, social functioning, 
fatigue and sleep disturbance, nausea, and constipation and diarrhoea [2]).  
In circumstances where a generic PBM has been shown to be appropriate for a condition, CSPBMs 
can be used in sensitivity analyses of the economic model to indicate how the use of the generic 
PBM, which although appropriate may be less sensitive or responsive to changes in health, may have 
impacted on incremental cost-effectiveness ratios.  
CSPBMs have a role in HTA external to the economic model to demonstrate additional benefits that 
may not be captured by the generic PBM and provide additional supporting evidence. CSPBMs also 
have a wide role outside of economic evaluation where they can be used to compare health and 
treatment effects across different studies within a patient group. The inclusion of CSPBMs in a wide 
range of studies provide utility values that are relevant for that condition as they take into 
consideration the specific aspects of health that are important for that condition. These utility values 
can be reported alongside the detailed HRQoL data provided from the condition-specific measure 
that the CSPBM is derived from (for example reporting condition-specific EORTC QLQ-C30 health-
related quality of life data alongside CSPBM data from the EORTC-8D for patients with prostate 
cancer [4]).  
 
3 Development issues 
3.1 Development from an existing condition-specific measure 
The advantage of deriving a preference-based measure from an existing condition-specific measure 
is that the existing measure has already been used in many studies, and therefore existing datasets 
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can be used to generate utility values. In addition, the existing measure is likely to have been 
validated and is likely to have evidence of good psychometric performance. 
Figure 1 outlines the six-stage process developed by researchers at the University of Sheffield to 
derive a CSPBM from an existing condition-specific measure [1]. Stages I to IV derive the 
classification system and stages V to VI derive the value set for every health state described by the 
classification system. The classification system consists of multiple dimensions with typically one 
item to reflect that dimension, with several levels of severity.  
Stages I to IV derive the classification system using a combination of factor analysis, Rasch analysis 
and classical psychometric analysis. Factor analysis can be used to either confirm the dimensional 
structure of the existing condition-specific measure, to propose a different dimensional structure 
indicating where dimensions are not independent or where items within the same dimension 
capture different concepts [1], or to propose a dimension structure for the existing condition-
specific measure which does not have one proposed by the instrument developer [5, 6]. Rasch 
analysis is a mathematical technique that enables qualitative data to be converted onto a continous 
latent scale using a logit model [7, 8]. Classical psychometric analyses are used to indicate the 
performance of each item within each dimension and include floor and ceiling effects, correlation 
between items and dimensions, responsiveness over time and levels of missing data.  
Stage I involves the derivation of the dimensions using a combination of factor analysis and the 
existing factor structure of the measure, and stage II uses Rasch analysis or item response theory 
and classical psychometric analysis to select the best item(s) to reflect each dimension in terms of 
coverage, ordering of levels, no differential item functioning across different groups, low floor and 
ceiling effects and good responsiveness. Stage III considers reducing the item levels to ensure that 
readers can accurately distinguish between each item level. Stage IV validates stages I-III, preferably 
on an independent dataset, to ensure the classification system has not been impacted on by the 
choice of dataset used to derive the classification system.  
Stage V entails a valuation study typically with members of the general population to value a sample 
of health states as it is generally infeasible to value all health states within the full classification 
system as typically there are too many. Stage VI involves regression analysis of the valuation data to 
produce a decrement from the reference level for every level of every dimension. This enables a 
utility value to be generated for every health state described by the classification system. Stages V 
and VI typically involve the same procedure as valuation of a generic PBM, see section 2 for an 
overview. One additional challenge is that some CSPBMs may be uni-dimensional, or have a uni-
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dimensional component, for example a CSPBM for flushing or common mental health problems. For 
uni-dimensional measures or components valuation can be adapted to take this uni-dimensionality 
into consideration through the selection of health states for valuation using Rasch analysis, which 
does not require independence of items [3, 9].  
At every stage clinical input is used and often the instrument developer of the existing condition-
specific measure is also involved. Some measures have also involved patients to ensure that the 
classification system includes all aspects that are important to patients (see for example [10]). Other 
measures have been developed using psychometric analyses on multiple existing condition-specific 
measures in order to select the best performing dimensions and items across these measures (for 
example [11]). 
3.2 ĞǀĞůŽƉŝŶŐĂŶĞǁŵĞĂƐƵƌĞ ?ĚĞŶŽǀŽ ? 
The advantage of developing a new measure is that it does not have to be based on an existing 
condition-specific measure as for some patient groups existing measures may not cover all 
important aspects of HRQoL. However there will be no pre-existing evidence on the psychometric 
performance of the new measure, which can be important for some international agencies when 
they are examining the appropriateness of the usage of a CSPBM.  It may therefore be necessary to 
establish the psychometric properties of the measure before it can be recommended for usage. 
Developing a new measure involves a modification of the six-stage process. Guidelines for the 
development of dimensions and items for new measures are available from the US Food and Drug 
Administration (FDA) [12]. Patient involvement is emphasised at every stage of developing a 
classification system for a new measure including both the generation and the validation of the 
content. Approaches in the literature include qualitative research with patients to identify 
dimensions, items and item wording, (for example [13]). The valuation of the measure is as 
described above in stages V and VI used to value a CSPBM derived from an existing condition-specific 
measure. 
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Figure 1 Six stages for deriving a condition-specific preference-based measure from an existing 
condition-specific (non-preference-based) measure 
 
 
 
  
Stage I: Establish dimensions 
x Factor analysis 
x Determine dimensionality 
Stage II: Eliminate and select items per 
dimension 
x Rasch analysis 
x Classic psychometric analysis 
Stage III: Explore item level reduction 
x Factor analysis to determine whether 
levels are disordered for any items 
Stage IV: Validation ʹ repeat stages I to III on 
other datasets 
x Ensure classification system is appropriate 
Stage V: Valuation exercise to elicit health state 
values for a sample of states 
x Use general population or patient values 
Stage VI: Model valuation results to produce 
utility scores for all health states 
x Regression analysis of valuation data 
Modified from source: [1] 
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4 Description of condition-specific preference-based measures 
Papers developing CSPBMs either from existing condition-speĐŝĨŝĐŵĞĂƐƵƌĞƐŽƌ ?ĚĞŶŽǀŽ ?ƚŚĂƚǁĞƌĞ
published in English were identified using 1) a literature search conducted in December 2010 [1] and 
updated in March 2016 for the purpose of this paper and 2) a recent review of the literature [14].  
Measures have been excluded that: do not provide utility weights; that do not anchor utilities on the 
1-0 full health-dead scale; that derive utilities by mapping from a condition-specific measure to own 
utility values (as this is mapping not a preference-based measure). In total 36 CSPBMs were 
identified across a range of 29 conditions. The CSPBMs are summarised in Table 1 and further details 
are provided in appendix 3. 
Table 1 Summary of existing condition-specific preference-based measures 
Aspect Extracted data 
Conditions Amyotrophic lateral sclerosis [15]; arthritis [16]; asthma [17, 18]; cancer 
[2, 10, 19, 20]; COPD [21]; common mental health problems [9, 22]; 
dementia [23-25]; diabetes [26, 27]; epilepsy [28]; erectile 
(dys)functioning [29]; flushing [3]; fragile X syndrome [30]; lung cancer 
[31, 32]; menopause [33]; multiple sclerosis [16]; myelofibrosis [11]; 
overactive bladder [5, 34]; paediatric asthma [35]; paediatric atopic 
dermatitis [6]; WĂƌŬŝŶƐŽŶ ?Ɛ disease [36]; prostate cancer [37, 38]; 
pulmonary hypertension [39]; schizophrenia or bipolar disorder [40]; 
sexual quality of life [56]; short bowel syndrome [57]; urinary 
incontinence [58,59]; lower urinary tract symptoms suggestive of benign 
prostatic obstruction [60]; venous ulceration [13]; vision/visual 
impairment [61,62,66,67] 
Classification system 
development 
De novo 4 [13,35,36,61] 
 Derived from an 
existing condition-
specific measure 
32[2,3,5,6,10,11, 15-17, 21, 22, 24-33, 38-40, 
53-60, 62] 
Classification system Number of 
dimensions 
2-10 
 Number of severity 
levels 
2-7 
 Number of health 
states 
9-6,000,000 
Preference elicitation 
technique 
DCE 1 [19] 
 DCE, ranking and VAS 1 [53] 
 LT-TTO 1 [57] 
 Rating scale and SG 1 [37] 
 SG  2 [6,58] 
 TTO 22 [2,3,9,11,13,16,20,21,25, 
28,29,30,33,34,39,55,56,60, 64,65,67] 
 VAS 1 [31,32] 
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Aspect Extracted data 
 VAS and SG 4 [26,27] 
 VAS and TTO 3 [40,59,66] 
Country providing 
preference weights 
Australia 2 [19,67] 
 Canada 2 [37,67] 
 Netherlands 7 [16,53,29,32,60] 
 Spain 1 [40] 
 Sri Lanka 1 [20] 
 UK 22 
[2,3,6,9,11,16,21,25,28,30,31,33,34,39,55,64,65] 
 US 5 [15,26,27,35,36,67] 
 Unclear 1 [66] 
Population providing 
preference weights 
General population 27 [2,3,6,9,11,13,15,16,19-21, 25,28,30-32, 
34,35,39,55-57,59,60,64,65,67] 
 Patients 6 [26,27,33,36,37,40,58] 
 Professionals and 
general population 
1 [53] 
 Students and general 
population 
1 [29] 
 Unclear 1 [66] 
Note: Numbers of extracted data refer to measures not papers, as the development of some 
measures is reported in multiple papers. Some measures provide preference weights for more than 
one country. 
 
5 Psychometric properties of condition-specific preference-based measures 
5.1 Psychometric performance of condition-specific preference-based measures in comparison to 
existing condition-specific measures 
There is limited evidence comparing CSPBMs to the existing condition-specific measure they are 
derived from [1, 14]. However, evidence suggests largely comparable psychometric performance in 
terms of discrimination across severity groups and responsiveness to change over time between the 
existing condition-specific measure and CSPBM for asthma, cancer, common mental health 
problems and overactive bladder [1]. 
5.2 Psychometric performance of condition-specific preference-based measures in comparison to 
generic preference-based measures 
There is limited evidence comparing CSPBMs and generic PBMs [1, 14]. However, evidence suggests 
that CSPBMs in asthma, cancer, common mental health problems and overactive bladder offer an 
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advantage for measuring milder health states, and are less prone to ceiling effects than the EQ-5D 
[1]. The ceiling effects of EQ-5D have been widely reported in the general literature examining the 
performance of EQ-5D (see for example [41]), and therefore for patients with mild health problems 
CSPBMs may be more likely to provide a more accurate measurement of HRQoL and capture change 
in HRQoL. The evidence also suggests that these CSPBMs and a measure in vision better 
discriminated across severity groups than the generic PBM they were compared to [1, 42-44]. It is 
recommended that the psychometric properties of any CSPBM are examined prior to their usage to 
inform HTA, and preferably compared to a generic PBM to confirm where they offer an advantage. 
Mean change over time and differences in utility values between different severity groups have been 
found to be smaller for CSPBMs than generic PBMs, with smaller standard deviation, in particular in 
comparison to EQ-5D [1] (although this may not always be the case [43, 45]). Any differences may 
impact on incremental cost-effectiveness ratios, and may potentially impact upon whether 
interventions are considered cost-effective. However, research in this area has been limited to a 
small number of datasets on a small number of conditions, CSPBMs and generic PBMs and the 
existing published evidence is unlikely to be representative across all CSPBMs. Further research in 
this area is encouraged. 
 
6 Selecting a measure for economic evaluation 
Recent ISPOR task force guidance provides a framework for researchers considering the collection of 
utility data for HTA [46]. An important consideration is the appropriateness of the measure for the 
condition and population, and the choice will also depend on the requirements of the agency to 
which the economic evaluation will be submitted (see [47]). However an important consideration is 
whether to use a generic PBM or a CSPBM. Table 2  outlines the advantages and disadvantages of 
generic PBMs and CSPBMs with reference to different criteria: completion of the measure by the 
patient; psychometric performance; HRQoL coverage; issues with the valuation process used to elicit 
the utility values; comparability of values for use in HTA.  
Overall CSPBMs offer advantages of lower patient burden for completion, are more relevant to the 
patient, are less likely to suffer from ceiling effects, and the existing condition-specific measures they 
are derived from are typically sensitive and responsive. However they suffer from disadvantages that 
they may not be able to capture the impact of all side-effects and comorbidities, their elicited utility 
values may be prone to exaggeration from focussing effects, the values they generate are not 
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directly comparable across different conditions, and they are not accepted in the base-case cost-
effectiveness analyses by many international agencies.  
It is important to note that the advantages and disadvantages of CSPBMs vary both by the exact 
measure and the patient group it is administered to. The content of CSPBMs varies widely, where for 
example a CSPBM in cancer [2, 10] may be perceived as more generic in its dimensions, and could 
ĞǀĞŶŚĂǀĞ ?ďŽůƚ-ŽŶ ?ĚŝŵĞŶƐŝŽŶƐĨŽƌĐĞƌƚĂŝŶĐĂŶĐĞƌƐ ?ǁŚĞƌĞĂƐŽƚŚĞƌ^WDƐ such as for flushing are 
uni-dimensional [3]. It is also important to note that the psychometric performance of measures 
differs across patient groups, and hence a measure that is appropriate for use in some patient 
groups is not necessarily appropriate in all patient groups.  
Generic PBMs offer the advantage that they offer comparability across patient groups and 
interventions, have no issues in their valuation and can arguably capture comorbidities where these 
occur in the generic dimensions of HRQoL. However they may not be responsive or sensitive and 
suffer from ceiling effects, and may not be relevant to the patient and potentially increase patient 
burden where they are included in addition to the condition-specific measures that are included for 
multiple reasons unrelated to populating the economic model. 
It has been argued that CSPBMs can provide utility values that are comparable to generic PBMs as 
they can be derived using the same methodology as a generic PBM (for example a large number of 
CSPBMs have been derived using time trade-off interview with the UK general population as also 
used by the EQ-5D UK value set), and utility values are anchored on a comparable 1-0 full health-
dead scale required to generate QALYs. However, there remains the issue of the differences in 
descriptive systems, and issues in the valuation of CSPBMs due to labelling the condition (disease 
labelling of health states can impact on elicited values [48]) and focussing effects (respondents focus 
only on the areas of HRQoL mentioned and exaggerate their importance) that may mean that there 
are important underlying issues of comparability. For this reason, to enable comparability in HTA 
conducted across interventions and patient groups a generic PBM is typically recommended for use 
in base case analyses, and a CSPBM is typically only recommended where evidence demonstrates a 
generic PBM is inappropriate (see for example prescriptive guidance by NICE[49]), or for use 
alongside a generic PBM in sensitivity analyses. 
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Table 2 Advantages and disadvantages of generic and condition-specific preference-based measures 
Aspect Generic preference-based measure Condition-specific preference-based measure 
Completion: patient 
burden 
May not be included in trial to reduce patient burden, though 
this may be more important for larger measures e.g. deriving 
SF-6D values from SF-36 
Condition-specific (non-preference-based) measures are 
typically included in trials, these responses can then be directly 
converted into CSPBM 
Completion: relevance 
to patient 
Not always relevant to the patient Relevant to the patient 
Performance: ceiling 
effects 
Evidence shows EQ-5D suffers from ceiling effects for some 
conditions  [1] 
Evidence demonstrates little ceiling effects [1] 
Performance: sensitivity 
and responsiveness 
Not sensitive and responsive for some conditions [50] Sensitive and responsive [50] 
Coverage: missing 
dimensions 
Includes important generic dimensions but may not include all 
symptoms that are important to the patient (though the 
impact of these may be captured if they impact on the generic 
dimensions) 
May not include all important generic dimensions but typically 
includes all important symptoms (though there may be 
exceptions e.g. a CSPBM in cancer may not include all 
symptoms relevant for all types of cancers) 
Coverage: side-effects 
and comorbidities 
Will capture more general side-effects and co-morbidities but 
may miss some symptomatic side-effects and co-morbidities 
(though again the impact of these may be captured if they 
impact on the generic dimensions) 
May not capture comorbidities or all relevant side-effects  
Valuation: condition 
labels 
No problems with valuation Use of condition labels in health state valuation exercises can 
impact on values e.g. inclusion of cancer label produces lower 
utility values than no condition label for the same health states 
[48] 
Valuation: focussing 
effect 
No problems with valuation Focussing on problems with a condition rather than generic 
dimensions may produce artificially lower utility values [51] and 
may mean respondents make assumptions about the generic 
aspects of health that are not mentioned 
Comparability across 
interventions and 
patient groups 
Comparable Limited comparability 
Acceptability for use in Accepted and typically recommended [52] Often not mentioned, or accepted only when the generic is 
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Aspect Generic preference-based measure Condition-specific preference-based measure 
HTA inappropriate [52] 
Notes: CSPBM  ? condition-specific preference based measure; HTA  ? health technology assessment. 
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7 Summary 
The paper provides an overview and summary of all existing CSPBMs, providing a resource for 
researchers. There are a large number of CSPBMs across a wide range of conditions, and the 
coverage of these measures varies from covering a wide range of dimensions to more symptomatic 
or uni-dimensional measures. CSPBMs have a useful role in HTA where a generic PBM is not 
appropriate, sensitive or responsive. Due to issues of comparability across different patient groups 
and interventions, their usage in HTA is typically limited to conditions where it is inappropriate to 
use a generic PBM, or in sensitivity analyses. Widespread use of CSPBMs rather than generic PBMs in 
HTA would reduce comparability of evaluations of interventions across different patient groups. For 
this reason CSPBMs are not recommended as a common replacement for generic PBMs, rather they 
offer important evidence alongside generic PBMs or where generic PBMs are inappropriate. 
Evidence suggests that CSPBMs offer an advantage in more accurate measurement of milder health 
states. However CSPBMs can fail to capture comorbidities and all side-effects. Mean change and 
standard deviation can differ to generic PBMs, and this may impact on incremental cost-
effectiveness ratios.  
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Online Appendix 
Table A1 Descriptive systems of condition-specific preference-based measures 
Condition: name of 
CSPBM (where available) 
First author Non-preference-based 
measure 
No. of 
dimensions 
Severity 
levels 
No. of states 
defined by 
system 
Dimensions 
Amyotrophic lateral 
sclerosis (ALS): ALS Utility 
Index 
Beusterien [15] Amyotrophic Lateral 
Sclerosis Functioning Rating 
Scale - Revised (ALSFRS-R) 
4 5-6 750 Speech and swallowing; eating, dressing and bathing; leg 
function; respiratory function 
Arthritis: HAQ-PBM Versteegh [16] Health Assessment 
Questionnaire (HAQ) 
5 4 1,024 Stand up from a straight chair; walk outdoors on flat ground; 
get on/off toilet; reach and get down a 5-pound object (such as 
a bag of sugar) from just above your head; open car doors 
Asthma: AQL-5D Young [17] Asthma Quality of Life 
Questionnaire (AQLQ) 
5 5 3,125 Concern about asthma; shortness of breath; weather and 
pollution stimuli; sleep problems; activity limitation 
Cancer: EORTC-8D Rowen [2] EORTC QLQ-C30 8 4-5 81,920 Physical functioning; role functioning; pain; emotional 
functioning; social functioning; fatigue and sleep disturbance; 
nausea; constipation and diarrhoea 
Cancer: QLQ-PBM Versteegh [16] EORTC QLQ-C30 8 2-4 32,768 Trouble taking a long walk; limited in doing either your work or 
other daily activities; pain; nausea; tired; difficulty in 
concentrating; worry; social activities 
Cancer: QLU-C10D King [10] EORTC QLQ-C30 10 4 1,048,576 Physical functioning; role functioning; social functioning; 
emotional functioning; pain; fatigue; sleep; appetite; nausea; 
bowel problems 
Chronic obstructive 
pulmonary disease 
(COPD): EXACT-U 
Petrillo [21] Exacerbations of chronic 
obstructive pulmonary dis- 
ease tool (EXACT) 
5 3-5 960 Chest discomfort; cough; shortness of breath with activity; 
psychological state; weak/tired 
Common mental health 
problems: CORE-6D 
Mavranezouilli 
[22] 
Clinical Outcomes in 
Routine Evaluation  ? 
Outcome Measure (CORE-
OM) 
6 3 729 Functioning  ? close relationships; functioning  ? social 
relationships; functioning  ? general; symptoms  ? anxiety; 
risk/harm to self; physical health 
Dementia: DEMQOL-U Mulhern [24, 25] DEMQOL (self-report) 5 4 1,024 Positive emotion; memory; relationships; negative emotion; 
loneliness 
Dementia: DEMQOL-
Proxy-U 
Mulhern [24, 25] DEMQOL-Proxy (carer 
proxy-report) 
4 4 
 
256 Positive emotion; memory; appearance; negative emotion 
Dementia: DQI Scholzel-
Dorenbos [53] 
Arons [54] 
Dementia Quality of Life 
Instrument 
6 3 729 Physical health; self-care; social functioning; mood; memory; 
orientation 
Diabetes: Diabetes Utility Sundaram [26, Audit of Diabetes- 5 3-4 768 Physical ability and energy level; relationships; mood and 
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Condition: name of 
CSPBM (where available) 
First author Non-preference-based 
measure 
No. of 
dimensions 
Severity 
levels 
No. of states 
defined by 
system 
Dimensions 
Index 27] Dependent Quality of Life 
(ADDQoL) plus additional 
items 
feelings; enjoyment of diet; satisfaction with managing diabetes 
Epilepsy: NEWQOL-6D Mulhern [28] Quality of Life in Newly 
Diagnosed Epilepsy measure 
(NEWQOL) 
6 4 4,096 Worry about attacks; depression; memory; cognition; stigma; 
control 
Erectile (dys)functioning Stolk [29] IIEF Index of Erectile 
Function 
2 5 25 Ability to attain an erection sufficient for satisfactory sexual 
performance; ability to maintain an erection sufficient for 
satisfactory sexual performance 
Flushing Young [3] Flushing Symptoms 
Questionnaire (FSQ) 
5 4-5 2,500 Redness of skin; warmth of skin; tingling of skin; itching of skin; 
difficulty sleeping 
Fragile X syndrome: ABC-
UI 
Kerr [30] Aberrant Behavior 
Checklist-Community 
(ABC-C) 
7 3 2,187 Mood changes quickly; easily distractible or restless, unable to 
sit still; aggressive towards others (verbally and physically); 
being impulsive (acting without thinking); repetitive speech; 
shows few social reactions to others and isolating yourself from 
others; repetitive hand, body or head movements 
Lung cancer Kind [31], Lamers 
[32] 
FACT-L 6 2  64 Physical; social/family; emotional; functional; symptoms - 
general: symptoms  ? specific 
Menopause Brazier [33] Menopause-specific quality 
of life questionnaire 
7 3-5 6,075 Hot flushes; aching joints/muscles; anxious/frightened feelings; 
breast tenderness; bleeding; vaginal dryness; undesirable 
androgenic signs 
Multiple sclerosis Goodwin [55] Multiple Sclerosis Impact 
Scale (MSIS-29) 
8 4 65,536 Physical; social; mobility; daily activities; fatigue; emotion; 
cognition; depression 
Multiple sclerosis: MSIS-
PBM 
Versteegh [16] Multiple Sclerosis Impact 
Scale (MSIS-29) 
8 4 65,536 Problems with your balance; being clumsy; limitations in your 
social and 
leisure activities at home; difficulties using your hands in 
everyday tasks; having to cut down the amount of time you 
spent on work or other daily activities; feeling mentally 
fatigued; feeling irritable, impatient or 
short tempered; problems concentrating 
Myelofibrosis: MF-8D Mukuria [11] MF-SAF and EORTC QLQ-
C30 
8 2-5 2,560 Physical functioning; emotional functioning; fatigue; itchiness; 
pain under ribs on left side; abdominal discomfort; bone or 
muscle pain; night sweats 
Overactive bladder: OAB-
5D 
Young [5] OABq overactive bladder 
questionnaire 
5 5 3,125 Urge to urinate; urine loss; sleep; coping; concern 
Paediatric asthma: Choiu [35] N/A 3 2-3 12  ? but only Symptoms; emotion; activity 
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Condition: name of 
CSPBM (where available) 
First author Non-preference-based 
measure 
No. of 
dimensions 
Severity 
levels 
No. of states 
defined by 
system 
Dimensions 
Paediatric Asthma Health 
Outcome Measure 
(PAHOM) 
10 are valid 
Paediatric atopic 
dermatitis 
Stevens [6] Un-named questionnaire on 
atopic dermatitis 
4 2 16 Activities; mood; settled; sleep 
Parkinson's disease Palmer [36] N/A 2 2-5 10 ŝƐĞĂƐĞƐĞǀĞƌŝƚǇ ?ƉƌŽƉŽƌƚŝŽŶŽĨƚŚĞĚĂǇǁŝƚŚ ?ŽĨĨ-ƚŝŵĞ ? ?ŝŵƉĂĐƚ
on QOL due to condition covering domains: social function, 
ability to carry out daily activities, psychological function) 
Prostate cancer: PORPUS-
U 
Krahn [38] Patient-Oriented Prostate 
Utility Scale 
10 4-6 6,000,000 Pain and disturbing body sensations; energy; support from 
family and friends; communication with doctor; emotional well-
being; urinary frequency; leaking urine; sexual function; sexual 
interest; bowel problems 
Pulmonary hypertension McKenna [39] Cambridge Pulmonary 
Hypertension Outcome 
Review (CAMPHOR) 
4 2-3 36 Social activities; travelling; dependence; communication 
Schizophrenia or bipolar 
disorder 
Montejo [40] Tolerability 
and Quality of Life 
questionnaire (TooL 
questionnaire) (Spanish 
version) 
8 4 65,536 Anxiety and depression; function capabilities; fatigue or 
weakness; body weight; stiffness and tremor; bodily 
restlessness; sexual function; dizziness or nausea 
Sexual quality of life: 
SQOL-3D 
Ratcliffe [56] Sexual quality of life 
questionnaire (SQOL) 
3 4 64 Sexual performance, sexual relationship, sexual anxiety 
Short bowel syndrome Lloyd [57] Short bowel syndrome 
health-related quality of life 
scale (SBS-QoL) 
6 2 64 Diet, eating and drinking habits; diarrhoea; fatigue/weakness; 
mobility and self-care/everyday activities; leisure 
activities/social life; emotional life 
Urinary incontinence Brazier [58] dŚĞ<ŝŶŐ ?ƐHealth 
Questionnaire (used for 
urinary incontinence and 
lower urinary tract 
symptoms) 
5 4 1,024 Role limitations; physical limitations; social limitations/family 
life; emotions; sleep/energy 
Urinary incontinence: 
Incontinence Utility Index 
(IUI) 
Cuervo [59] Incontinence Quality of Life 
Questionnaire (I-QOL) and 
Neurogenic Module 
5 3 243 Depression; urine smell; sleep; bladder control; drinks 
Lower urinary tract 
symptoms (LUTS) 
suggestive of benign 
Kok [60] International Prostate 
Symptom Score (IPSS) 
2 3 9 Irritative (frequency, urgency, nocturia); obstructive 
(incomplete emptying, intermittency, weak stream, hesitancy) 
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Condition: name of 
CSPBM (where available) 
First author Non-preference-based 
measure 
No. of 
dimensions 
Severity 
levels 
No. of states 
defined by 
system 
Dimensions 
prostatic obstruction 
Venous ulceration Palfreyman [13] N/A 5 3-5 720 Pain;  mobility; mood; smell; social activities 
Vision/visual impairment: 
VisQoL/AQoL-7D 
Misajon [61] N/A 6 5-7 45,360 Physical well-being; independence; social well-being; emotional 
well-being; self-actualization; planning and organization 
Vision: VFQ-UI Kowalski [62] National Eye Institute Visual 
Function Questionnaire-25 
(NEI VFQ-25) 
6 5 15,625 Near vision; social vision; distance vision; role difficulty; vision 
dependency; vision-related mental health 
Note: Table updated and modified from [63]. Key: ABC-C  ? Aberrant Behaviour Checklist-Community; ABC-UI  ? Aberrant Behaviour Checklist-Utility Index; ADDQoL  ? Audit of Diabetes-
Dependent Quality of Life; ALS  ? amyotrophic lateral sclerosis; ALSFRS-R  ? Amyotrophic Lateral Sclerosis Functioning Rating Scale - Revised;  AQLQ  ? Asthma Quality of Life Questionnaire; 
AQL-5D  ? Asthma Quality of Life 5 dimension; CAMPHOR  ? Cambridge Pulmonary Hypertension Outcome Review; CORE-OM  ? Clinical Outcomes in Routine Evaluation - Outcome Measure; 
CORE-6D  ? Clinical Outcomes in Routine Evaluation 6 dimension; COPD  ? Chronic obstructive pulmonary disease; DEMQOL  ? Dementia-specific Quality of Life; DEMQOL-Proxy  ? Dementia-
specific Quality of Life, for carers; DEMQOL-Proxy-U  ? Dementia-specific Quality of Life-Utility, for carers; DEMQOL-U  ? Dementia-specific Quality of Life - Utility; DQI  ? Dementia Quality of 
Life Instrument EORTC-8D - European Organisation for Research and Treatment of Cancer 8 dimension; EORTC-C30  ? European Organisation for Research and Treatment of Cancer Core 
Quality of Life Questionnaire; EXACT  ? Exacerbations of chronic obstructive pulmonary disease tool; EXACT-U  ? Exacerbations of chronic obstructive pulmonary disease tool-Utility; FACT-L  ? 
Functional Assessment of Cancer Therapy-Lung; FSQ  ? Flushing Symptoms Questionnaire; HAQ  ? Health Assessment Questionnaire; HAQ-PBM  ? Health Assessment Questionnaire-Preference-
Based Measure; IIEF  ? International Index of Erectile Function; IPSS  ? International Prostate Symptom Scale; I-QOL  ? Incontinence Quality of Life Questionnaire; IUI  ? Incontinence Utility 
Index; LUTS  ? Lower urinary tract symptoms; MF-8D  ? Myelofibrosis-specific Quality of Life 8 dimension; MF-SAF - Myelofibrosis Symptom Assessment Form; MSIS-PBM  ? Multiple Sclerosis 
Impact Scale-Preference-Based Measure; MSIS-29  ? Multiple Sclerosis Impact Scale-29; N/A  ? Not available; NEI VFQ-25  ? National Eye Institute Visual Function Questionnaire-25; NEWQOL-
6D  ? Quality of Life in Newly Diagnosed Epilepsy Instrument;  NEWQOL-6D  ? Quality of Life in Newly Diagnosed Epilepsy Instrument 6 dimension; OABq  ? Overactive Bladder Questionnaire; 
OAB-5D  ? Overactive Bladder Questionnaire 5 dimension; PAHOM  ? Paediatric Asthma Health Outcome Measure; PORPUS-U- Patient-Oriented Prostate Utility Scale; QLQ-PBM  ? Quality of 
Life Questionnaire-Preference-Based Measure; QLU-C10D  ? Core Quality of Life Utility 10 dimension; SBS-QoL  ? Short Bowel Syndrome health related quality of life scale; SQOL  ? Sexual 
Quality of Life; SQOL-3D  ? Sexual Quality of Life 3 dimension; VFQ-UI  ? Visual Function Questionnaire-Utility Index; VisQoL/AQoL-25  ? Vision-related Assessment of Quality of Life 7 dimension. 
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Table A2 Valuation of condition-specific preference-based measures 
Condition: name of CSPBM (where 
available) 
First author Theory and model type Preference elicitation 
technique 
Population Country 
Amyotrophic lateral sclerosis (ALS): 
ALS Utility Index 
Beusterien [15] Decomposed  ? multiplicative VAS for states and for the 
levels per dimension and SG 
Gen. population US 
Arthritis: HAQ-PBM Versteegh [16] Statistical  ? additive TTO Gen. population Netherlands 
Asthma: AQL-5D Yang [64] Statistical  ? additive TTO Gen. population UK 
Cancer: EORTC-8D Rowen [2] 
Kularatna [20] 
Statistical  ? additive TTO 
TTO 
Gen. population 
Gen. population 
UK 
Sri Lanka 
Cancer: QLQ-PBM Versteegh [16] Statistical  ? additive TTO Gen. population Netherlands 
Cancer: QLU-C10D Norman [19] Statistical  ? additive DCE with duration Gen. Population Australia 
Chronic obstructive pulmonary disease 
(COPD): EXACT-U 
Petrillo [21] Statistical - additive TTO Gen. population UK 
Common mental health problems: 
CORE-6D 
Mavranezouilli [9] Statistical  ? additive TTO Gen. population UK 
Dementia: DEMQOL-U Rowen [65] 
Mulhern [25] 
Statistical  ? additive TTO Gen. population UK 
Dementia: DEMQOL-Proxy-U Rowen [65] 
Mulhern [25] 
Statistical  ? additive TTO Gen. population UK 
Dementia: DQI Scholzel-
Dorenbos [53] 
Maps DCE latent utilities onto EQ-5D 
utilities using rank/VAS data of DQI 
and EQ-5D 
DCE, ranking and VAS Professionals working with 
patients with dementia, Gen. 
population 
Netherlands 
Diabetes: Diabetes Utility Index Sundaram [26, 27] Decomposed  ? multiplicative VAS and SG  Patients US 
Epilepsy: NEWQOL-6D Mulhern [28] Statistical  ? additive TTO Gen. population UK 
Erectile (dys)functioning Stolk [29] All states valued TTO Gen. population and students Netherlands 
Flushing Young [3] Maps Rasch logit scores onto mean 
utilities  ? additive 
TTO Gen. population UK 
Fragile X syndrome: ABC-UI Kerr [30] Statistical - additive TTO Gen. population UK 
Lung cancer Kind [31] 
Lamers [32] 
Statistical  ? additive 
Statistical - additive 
VAS 
VAS 
Gen. population 
Gen. population 
UK 
Netherlands 
Menopause Brazier [33] Statistical - additive TTO Patients UK 
Multiple sclerosis Goodwin [55] Statistical - additive TTO Gen. population UK 
Multiple sclerosis: MSIS-PBM Versteegh [16] Statistical - additive TTO Gen. population Netherlands 
Myelofibrosis Mukuria [11] Statistical - additive TTO Gen. population UK 
Overactive bladder: OAB-5D Yang [34] Statistical  ? additive TTO Gen. population UK 
Paediatric asthma: Paediatric Asthma 
Health Outcome Measure (PAHOM) 
Choiu [35] Power function used to convert VAS to 
SG, all states valued using VAS 
VAS and SG Gen. population US 
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Condition: name of CSPBM (where 
available) 
First author Theory and model type Preference elicitation 
technique 
Population Country 
Paediatric atopic dermatitis Stevens [6] All states valued SG Gen. population UK 
Parkinson's disease Palmer [36] All states valued VAS and SG Patients US 
Prostate cancer: PORPUS-U Tomlinson [37] Decomposed  ? multiplicative Rating scale for states and 
for the levels per dimension 
and SG 
Patients Canada 
Pulmonary hypertension McKenna [39] Statistical  ? additive TTO Gen. population UK 
Schizophrenia or bipolar disorder Montejo [40] Decomposed  ? multiplicative VAS for states and for the 
levels per dimension and TTO 
Patients Spain 
Sexual quality of life: SQOL-3D Ratcliffe [56] Statistical  ? additive TTO Gen. population UK 
Short bowel syndrome Lloyd [57] Statistical  ? additive LT-TTO Gen. population UK 
Urinary incontinence Brazier [58] Statistical - additive SG Patients  
 
UK 
Urinary incontinence: Incontinence 
Utility Index (IUI) 
Cuervo [59] Decomposed  ? multiplicative VAS for states and for the 
levels per dimension and TTO 
Gen. population UK 
Lower urinary tract symptoms (LUTS) 
suggestive of benign prostatic 
obstruction 
Kok [60] All states valued TTO Gen. population Netherlands 
Venous ulceration Palfreyman [13] Statistical  ? additive TTO Gen. population UK 
Vision/visual impairment: 
VisQoL/AQoL-7D 
Peacock [66] Decomposed  ? multiplicative VAS for the levels per 
dimension and TTO 
Unclear Unclear 
Vision: VFQ-UI Rentz [67] Maps item response theory scores 
onto mean utilities  ? additive 
TTO Gen. population Australia, 
Canada, UK, US 
Note: Table updated and modified from [63]. ).  
#
 Preference elicitation technique is reported only if it was used to produce the recommended utility scores for all health states.  Statistical = 
statistical inference (regression analysis); decomposed = multi-attribute utility theory (MAUT) or combination of MAUT and statistical inference.  DCE: discrete choice experiment; Gen. 
population: general population; LT-TTO: lead-time trade-off; TTO: time trade-off; SG: standard gamble; VAS: visual analogue scale 
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